Search
forLearn
5 / 801 resultslearn tangerine extract
learn Cinchona pubescens
learn Citrus Reticulata Peel
learn Geraniol
Research
5 / 366 results
research Anidulafungin-Induced Alopecia
A woman's hair loss was probably caused by the antifungal drug anidulafungin.
research Hot Flashes in a Young Girl: A Wake-up Call Concerning Serenoa repens Use in Children
Serenoa repens (saw palmetto) may cause side effects like hot flashes in children and needs more research for safety in pediatric use.
research Atypical post-finasteride syndrome: A pharmacological riddle
Finasteride and dutasteride can cause severe, lasting side effects.
research Acneiform Rash Caused by an Unlikely Drug: Topiramate
A man got a rare rash from the drug topiramate, which went away after he stopped taking it.
research Alopecia associated with agomelatine use: a case report
Stopping the antidepressant agomelatine improved hair loss in a patient.
Community Join
5 / 1000+ resultscommunity Positive Hair Result in Patient using Tirzepatide
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
community Hair Tattoo as a substitue to hair transplant
A hair tattoo substitute for a hair transplant, which many people felt was not a good idea. Several treatments were suggested as alternatives, such as Scalp Micro Pigmentation (SMP) and wigs.
community Thinking about starting Fin for receding hairline. 5 year old male
A 5-year-old male considering using finasteride to prevent receding hairline, with suggestions ranging from topical minoxidil and estrogen treatments to hair transplantation and shaving.
community Sandalore (Givaudan) concentration application
The conversation discusses using Sandalore for hair loss treatment, with a focus on finding the correct concentration for a topical lotion. The consensus is to start with a 0.1% concentration due to potential scalp irritation at higher levels.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.